Prisys Biotechnology Co., Ltd., a pioneering high-tech enterprise in Shanghai, is making significant strides in the field of preclinical and quasi-clinical drug evaluation, focusing on innovative drug technologies. Renowned for its precision and excellence, Prisys Biotech has been recognized as a "Shanghai Specialized and New Small and Medium Enterprise" and boasts full AAALAC accreditation, underscoring its commitment to the highest standards of animal welfare and research quality.
Enhanced Preclinical R&D for CNS Therapeutics
Prisys Biotech is at the forefront of enhancing research and development for central nervous system (CNS) therapeutics. The company has developed a suite of advanced cross-reactive models and platforms designed to accelerate the discovery and validation of new treatments:
- Precision Platform for Trans-BBB Delivery: Utilizing intraprocedural MRI guidance, this platform enables precise and targeted convection enhanced delivery (CED) to specific brain structures. This technology is crucial for the growth of the neuro-therapeutic pipeline, ensuring accurate delivery of therapeutics across the blood-brain barrier.
- 3D-AI NHP BehaviorAtlasTM - 2nd Generation: The upgraded algorithm and system analyze non-human primate (NHP) gait parameters, making it ideal for quantifying ataxia and neuro-muscular disorders. This tool represents a significant advancement in the assessment of motor functions and the effects of neuro-therapeutic interventions.
- Expansion of NHP Models of CNS Disorders: With an investment exceeding $1.5 million, Prisys Biotech is developing new models for conditions such as stroke, Parkinson's disease (PD), Alzheimer's disease (AD), and epilepsy. The company invites co-development opportunities to enhance the transformation of therapeutics for both common and rare CNS disorders.
Comprehensive Services and Innovative Facilities
Prisys Biotech provides a comprehensive range of services, including disease model development, pharmacological and pharmacodynamic research, safety evaluation, biomarker research, and validation of mechanistic concepts. These services leverage various animal models, predominantly NHPs and experimental dogs, to study diseases affecting the nervous, cardiovascular, metabolic, and renal systems.
In 2022, Prisys Biotech established a state-of-the-art translational medical center that aligns with pharmaceutical industry standards. This facility integrates several key functions:
- NHP Model Development: Creating sophisticated models for a wide range of diseases to support drug discovery and development.
- Clinical-Level Research: Conducting research activities that mimic clinical conditions, enhancing the relevance and applicability of preclinical findings.
- Industrial-Scale Research Capabilities: Supporting large-scale studies and collaborations with pharmaceutical companies and research institutions.
- Exemplary Animal Welfare Practices: Maintaining the highest standards of animal care and welfare, essential for ethical and reliable research outcomes.
Prisys Biotech is dedicated to becoming a leader in large animal pharmacological and pharmacodynamic research, contributing significantly to the advancement of CNS therapeutics and other medical fields. Through its innovative technologies, comprehensive services, and commitment to excellence, Prisys Biotech is poised to transform the landscape of preclinical drug development.
